High concentrations of TGFβ in the target tissues of patients with cGVHD contribute to scleroderma and BOS development, and reducing TGFβ production, may improve organ function and reverse cGVHD fibrosis (32, 39, 40). The gene discussed is TGFB1; the disease is Buschke-Ollendorff syndrome.